PAFSC’s 1st Committee to Review 7 Products Including BMKK’s Apixaban on Nov. 30

November 20, 2012
The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) First Committee on Drugs will review seven products/indications, including Bristol-Myers K.K.’s (BMKK) novel oral factor Xa inhibitor Eliquis Tablets 2.5 mg/5 mg (apixaban), on November 30. Eliquis, an anticoagulant agent, which was...read more